Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Mereo BioPharma Group (MREO) Operating Expenses: 2016-2024

Historic Operating Expenses for Mereo BioPharma Group (MREO) over the last 9 years, with Dec 2024 value amounting to $47.4 million.

  • Mereo BioPharma Group's Operating Expenses rose 10.05% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.7 million, marking a year-over-year increase of 17.71%. This contributed to the annual value of $47.4 million for FY2024, which is 32.15% up from last year.
  • According to the latest figures from FY2024, Mereo BioPharma Group's Operating Expenses is $47.4 million, which was up 32.15% from $35.8 million recorded in FY2023.
  • Over the past 5 years, Mereo BioPharma Group's Operating Expenses peaked at $55.6 million during FY2022, and registered a low of -$6.3 million during FY2020.
  • Over the past 3 years, Mereo BioPharma Group's median Operating Expenses value was $47.4 million (recorded in 2024), while the average stood at $46.3 million.
  • As far as peak fluctuations go, Mereo BioPharma Group's Operating Expenses slumped by 163.68% in 2020, and later spiked by 440.59% in 2022.
  • Mereo BioPharma Group's Operating Expenses (Yearly) stood at -$6.3 million in 2020, then spiked by 264.21% to $10.3 million in 2021, then surged by 440.59% to $55.6 million in 2022, then plummeted by 35.50% to $35.8 million in 2023, then skyrocketed by 32.15% to $47.4 million in 2024.